Mary Caffrey

FDA clears hands-free on-body injector for isatuximab in multiple myeloma, cutting treatment time and reactions while matching IV efficacy.

emtelligent turns unstructured data into coded clinical insights, powering payer and oncology workflows to improve trial screening, EHR-to-EDC transfer, and decisions.

ViroMissile shares phase 1 IDOV-Safe oncolytic virus results, showing IV activity in pMMR/MSS metastatic colorectal cancer and fueling US phase 2 plans.

At ESMO GI, Merck’s next-generation KRAS-inhibitor calderasib plus EGFR-targeting cetuximab and chemotherapy produce remarkable progression-free survival results for patients with previously untreated colorectal cancer.

SYNC-T from Syncromune delivers a 4-part localized immunotherapy regimen for metastatic prostate cancer, showing high response rates with low toxicity.

Kazia Therapeutics advances paxalisib, a dual PI3K/mTOR inhibitor, into triple-negative breast cancer, boosting immunotherapy responses with early promising data.

As CAR T-cell therapy expands into outpatient and community settings, Reimagine Care and The Center for Cancer and Blood Disorders are creating a monitoring infrastructure to support patients and caregivers alike.

Chemo-free zanubrutinib plus rituximab in phase 3 MANGROVE cuts progression/death risk 43% vs BR for frontline mantle cell lymphoma.

Reconstructed Kaplan-Meier data benchmark durability of CAR T-cell therapy, bispecific antibodies, and zanubrutinib combos for relapsed follicular lymphoma.

Community Oncology Alliance AI Playbook powers digital health practice transformation, guiding teams to choose AI partners, protect data, and expand efficient care.

As SYMPATICO publishes final data for ibrutinib–venetoclax relapsed mantle cell lymphoma, a new commentary discusses how combinations with zanubrutinib and sonrotoclax-era could take over.

Summary of Nonconsensus Discussions: Bridging the Gaps in Health Equity & Access in Multiple Myeloma | May 2, 2026, Tampa, Florida

Our annual ASCO recap issue will have a new section, "On the Horizon," featuring emerging science, therapies, and technology.

Epcoritamab shows high rates of first-line response and MRD negativity in older patients with chemo-ineligible DLBCL, whether used alone or with R-mini-CHOP.

SEER and Medicare data project rising DLBCL and MCL cases through 2032, intensifying payer strain and demand for Brukinsa, Calquence, and CAR-T access.

With an FDA approval for its companion diagnostic in bladder cancer, Natera extends its Treatment on MRD strategy, deferring adjuvant immunotherapy for patients with negative results for disease following surgery.

Flatiron Telescope uses AI and transparent SQL to turn real-world evidence into quick turnaround oncology research and FDA-ready analytics.

Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center details evolving mantle cell lymphoma care: ECHO acalabrutinib-BR and chemo-free zanubrutinib BOVen triplets challenge standards.

Investigators described the combinations as a potential new standard of care in second-line HR+/HER2− advanced breast cancer.

ASCO: City of Hope investigator highlights mosunetuzumab plus polatuzumab vedotin ADC/bispecific combo boosting PFS in LBCL with manageable adverse events outpatient.

McKesson and The US Oncology Network find EOM attribution often mislabels cancer episodes—especially oral therapy—threatening value-based care accuracy and accountability.

Real-world ASCO data link GLP-1 drugs to markedly longer survival across common cancers, raising new questions on mechanism and trials.

Cardinal Health hires ex-FCS leader Nathan Walcker to drive The Specialty Alliance's growth, including managed services in gastroenterology and urology.

The lead investigator for SUCCESSOR-2 discusses the potency of a potential successor to pomalidomide in treatment of multiple myeloma, with survival outcomes that rival CAR T-cell therapy.

Although smaller studies have highlighted CAR T differences in access and outcomes, new research shows the full extent of the issue.

The bispecific T-cell engager could fulfill an unmet need among patients with mantle cell lymphoma who progress after treatment with a BTK inhibitor.

On paper, the OCM cost Medicare millions. A decade later, physicians say its lessons are priceless.

Remote therapeutic monitoring with ePROs powered by AI cuts hospitalizations and boosts therapy time—now a key oncology leader promotes guidelines and reimbursement to make it standard of care.

Canopy remote therapeutic monitoring with ePROs cuts hospitalizations and extends time to discontinuation in metastatic cancer, saving millions.

Data presented at ASCO support wider use of prophylactic therapy to prevent cytokine release syndrome as efforts expand to promote bispecifics in treatment of multiple myeloma.